Repositioning Candidate Details

Candidate ID: R0493
Source ID: DB01328
Source Type: approved; investigational
Compound Type: small molecule
Compound Name: Cefonicid
Synonyms: (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefonicid
Molecular Formula: C18H18N6O8S3
SMILES: [H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O
Structure:
DrugBank Description: A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.
CAS Number: 61270-58-4
Molecular Weight: 542.566
DrugBank Indication: For the treatment of bacterial infections caused by susceptible microorganisms.
DrugBank Pharmacology: Cefonicid is a second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.
DrugBank MoA: Cefonicid, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins.
Targets: Penicillin-binding protein 1A inhibitor; Peptidoglycan synthase FtsI inhibitor; Penicillin-binding protein 1B inhibitor; D-alanyl-D-alanine carboxypeptidase DacB inhibitor; Penicillin-binding protein 2 inhibitor
Inclusion Criteria: Indication associated